
SynAct Q4 2024 - Successful Rights Issue Funds 2025

Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and directed share issue in December-January. This will fund 2025 and the recruitment of 240 patients in the phase IIb study Advance.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[SynAct Q4 2024 - Successful Rights Issue Funds 2025](#)